The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …

Background Immunotherapy initiated early after first presentation of relapsing-remitting
multiple sclerosis is associated with improved long-term outcomes. One can therefore …

Background Natalizumab is a humanized monoclonal antibody used for treatment of highly
active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing …

Controlling for confounding bias is crucial in causal inference. Distinct methods are currently
employed to mitigate the effects of confounding bias. Each requires the introduction of a set …

The care of multiple sclerosis (MS) in France is based on two complementary interlinked
networks: MS expert centers in university hospitals and regional networks of neurologists …

Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for
treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of …

Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …

Objective: Study aims were to determine the frequency of highly active disease in pediatric
multiple sclerosis (MS), the response to natalizumab (NTZ) and fingolimod (FTY) treatment …

Randomised clinical trials are the primary source of evidence, guiding the use of disease-
modifying drugs in multiple sclerosis. However, the spectrum of questions that can be …